Glykit-M 1 Forte Tablet ER is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 1000mg extended-release. It is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled with diet and exercise alone. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control. The extended-release formulation allows for once-daily dosing, promoting better patient adherence and reducing gastrointestinal side effects commonly associated with immediate-release metformin. Glykit-M 1 Forte is typically prescribed as part of a comprehensive diabetes management plan including diet modification and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Caution is advised in patients with cardiovascular disease or those undergoing radiologic studies involving iodinated contrast agents. Regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia and lactic acidosis is essential. This combination therapy offers a synergistic approach to glycemic control, improving patient outcomes in type 2 diabetes management.